CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Aeglea Bio Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Aeglea Bio Therapeutics Inc
901 S. Mopac Expressway
Ste. 250, Barton Oaks Plaza One
Phone: (512) 942-2935p:512 942-2935 AUSTIN, TX  78746  United States Ticker: AGLEAGLE

Business Summary
Aeglea BioTherapeutics, Inc. is a biotechnology company engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its lead product candidate, pegzilarginase, is engineered to degrade the amino acid arginine and is being developed to lower arginine levels in patients with Arginase I Deficiency. Its AEB4104 product candidate is a recombinant human enzyme that degrades the amino acid homocysteine and its oxidized form homocystine. It is developing AEB4104 for the treatment of patients with cystathionine beta synthase (CBS) deficiency. Its AEB5100 products candidate is a recombinant human enzyme that degrades plasma cystine and cysteine. It is developing AEB5100 product candidate for the treatment of patients with cystinuria. Its AEB3103 product candidate is an engineered human enzyme that targets the degradation of the amino acid cysteine/cystine.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201912/31/2018YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the board Russell J.Cox 55 1/1/2019 6/1/2015
President, Chief Executive Officer, Chief Medical Officer, Director Anthony G.Quinn 57 10/10/2019 3/1/2016
Chief Financial Officer, Vice President Charles N.York 42 9/1/2015 7/1/2014
9 additional Officers and Directors records available in full report.

Business Names
Business Name
AE4ase, Inc.
AE5ase, Inc.
AE6ase, Inc.
5 additional Business Names available in full report.

General Information
Number of Employees: 75 (As of 9/30/2019)
Outstanding Shares: 28,985,518 (As of 11/1/2019)
Shareholders: 37
Stock Exchange: NASD
Federal Tax Id: 464312787
Fax Number: (512) 872-5121


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, December 14, 2019